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Abstract
Human cortical somatosensory evoked potentials
(SEPs), which are presumably generated in afferent tha-
lamocortical and early cortical fibers, reveal a burst of
superimposed early (N20) high-frequency oscillations
(HFOs), around 600 Hz. There is increasing evidence of
an imbalance of thalamocortical systems in schizophren-
ic patients. In order to assess correlations between so-
matosensory evoked oscillations and symptoms of
schizophrenia, we investigated median nerve SEPs in 20
inpatients and their age-matched and gender-matched
healthy controls using a multichannel EEG. Dipole
source analysis and wavelet transformation were per-
formed before and after application of a 450-Hz high-
pass filter. In schizophrenics, the maximum HFOs oc-
curred with a significantly prolonged latency. There was
also a higher amplitude (energy) in the low-frequency
range of the N20 component compared with the con-
trols. Importantly, amplitudes (energy) of HFOs were
inversely correlated with symptoms of formal thought
disorder and delusions. Alterations of the thalamocorti-
cal somatosensory signal processing in schizophrenia
with absence of an early HFO – assumed to be of inhibito-
ry nature – could indicate a dysfunctional thalamic inhibi-
tion with increased amplitudes of N20, paralleled by
enhanced positive schizophrenic symptoms.
Copyright © 2004 S. Karger AG, Basel
Introduction
The central anatomic position and extensive cortical
interconnectivity of the thalamus, and its regulatory ‘gat-
ing’ function for the input of most of the sensory systems
have contributed to the concept of thalamic generator of
the brain [1–3]. Thalamic dysfunction is regarded as a
part of large-scale filter failure in the pathogenesis of psy-
chotic diseases [4]. In schizophrenia, earlier hypotheses of
a filter deficit for sensory information [5, 6] were ex-
tended when neuropsychological findings pointed in-
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creasingly to dysfunctional cortico-striato-thalamic con-
nections [7, 8]. Recent studies on information processing
deficits in schizophrenia [9, 10] strongly suggest a rela-
tionship with abnormal thalamocortical connections, in
particular with prefrontal and temporolimbic areas. Tha-
lamic alterations in schizophrenia were widely demon-
strated anatomically [11–19] and metabolically [16, 20–
24], though with nonuniform results.
Neurophysiologically, the central role of the thalamus
in the regulation of cognitive and sensory cortical input is
mainly supported by alterations of preattentive sensory
gating in schizophrenic patients, predominantly demon-
strated by a loss of inhibitory function as indicated by a
deficient prepulse inhibition [2, 25, 26]. Still, electrophys-
iological studies – accurate in measurements of the time
between stimulus and response – of possible thalamocor-
tical dysfunctions in schizophrenia other than the startle
response are rare. Previously, the variability of wave
shapes of somatosensory evoked potentials (SEPs) in
chronic schizophrenics was described as a high early and
low late stability of amplitudes [27, 28] probably depend-
ing on the acuity of the disease. Jones and Miller [29] tried
to establish latency differences of SEPs between schizo-
phrenics and healthy controls as a measure of intrahemis-
pheric transfer, but these findings were not shown to be
replicable [30]. Nevertheless, by studying SEPs, nowadays
the more detailed information on underlying physiologi-
cal processes, derived from animal studies, can be related
to modern noninvasive studies of somatosensory func-
tioning in humans.
Human median nerve SEPs provide the possibility of
investigating thalamocortical and early cortical process-
ing more intensely by means of advanced analysis filter-
ing tools [31]: SEPs of the median nerve when digitally
high-pass filtered show a brief oscillatory burst with low
amplitudes (!500 nV) and high frequency (600 Hz).
These high-frequency oscillations (HFOs) are superim-
posed on the primary cortical low-frequency response
represented by a parietal negativity peak component ap-
proximately 20 ms after stimulation, i.e., the N20 [32].
According to Allison et al. [33], the primary N20 compo-
nent is mainly generated by excitatory postsynaptic po-
tentials in the proximal segments of apical dendrites of
pyramidal cells in Brodman area 3b. On the other hand,
various cellular sites have been considered responsible for
the HFOs, namely the thalamus and/or thalamocortical
afferents [34], intracortical pyramidal cells [35] or post-
synaptic axons [36], and, lately, inhibitory interneurons
[37]. One generator for the HFOs was localized by means
of magnetoencephalography near the N20 source in the
hand area 3b [26, 38], possibly reflecting presynaptic
repetitive discharges that were conducted in the terminal
segments of thalamocortical axons and/or postsynaptic
segments derived from neocortical neurons.
In association with multichannel EEG studies, dipole
source analysis – a modern noninvasive method that
allows localization of the main neuronal generators in the
cortex by estimating intracerebral sources for surface
scalp-recorded waveforms [39] – made it possible to dem-
onstrate HFOs originating close to the thalamus [40, 41].
This source is assumed to be generated in the deep axon
segments of thalamocortical fibers as it was most active
between the brain stem (P14) and cortical sources (N20).
Presynaptic activity, arriving at the sensorimotor cortex,
was thought to originate, at least partially, in the deep
axon segments of thalamocortical fibers. This source was
also detected by invasive recordings in primates and
humans [34, 42, 43]. Further intrathalamic SEP record-
ings in patients have confirmed a local high-frequency
activity superimposed on the thalamic P16 [44].
At present, these two evoked somatosensory responses,
N20 (low frequency) and 600 Hz (high frequency), have
been shown to be independent components of SEPs: they
can be dissociated functionally by variation of stimulus
intensities [45], stimulus rates [41], double pulse stimula-
tion [44], vigilance states [32, 46, 47], and by interference
with different somatosensory stimuli [38] or motor tasks
[48]. Thus, the ‘SEP gating’ of HFOs is thought to reflect
timing processes of repetitive cerebral population spikes
with regular amplitude recruitment [49] occurring for all
components independent of, for example, the motor
task.
In order to further investigate thalamic dysregulation
as a pathophysiological factor in schizophrenia, an abnor-
mal pattern of assumed thalamocortical HFOs should be
present in these patients. The principal aim of this investi-
gation was to test the hypothesis of thalamocortically gen-
erated SEP alterations in schizophrenic patients by a non-
invasive electrophysiological study with multichannel
EEG, followed by an analysis of low-frequency oscilla-
tions and HFOs, in relationship to the severity of symp-
toms.
Methods and Materials
Subjects
Twenty right-handed inpatients with schizophrenia (5 females,
15 males) were recruited at the Psychiatry Department of the Uni-
versity Hospital of Aachen, Germany. They all met the Axis I diag-
noses for schizophrenia according to the DSM-IV criteria [50], con-
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firmed by a detailed clinical interview and review of hospital rec-
ords.
The mean age of the schizophrenic patients was 30.30 years (SD
9.33) with a range of 18–48 years. The mean age at illness onset was
25.80 years (SD 8.76), and the mean duration of illness since first
onset was 4.45 years (median 3.00, SD 4.90) with an average episode
number of 2.38 (SD 1.60), including 7 chronic patients with no full
remissions. The average length of inpatient hospital stay at the time
of the investigation was 56.72 days (median 36, SD 35.63). Before
entering the study, the patients were screened for severe somatic ill-
nesses. Psychiatric exclusion criteria were comorbidity with a major
depressive episode and other affective disorders, current (!3
months) substance-related disorders, and all cognitive and mental
disorders due to a medical condition. Seven patients revealed a past
history of alcohol or substance abuse or dependence.
An age-matched and gender-matched control group was selected
from the hospital staff members, medical, and other university stu-
dents without any current or past psychiatric history, or major
somatic illnesses. The mean age of controls was 31.11 years (SD
8.63). The patient group and control group did not differ in their age
distributions.
After being orally informed of all details of the study, all partici-
pants gave their informed consent. Patients were tested during a sta-
ble period of their hospitalization.
Medication Status
All patients were treated with antipsychotic medications; 16
patients received atypical antipsychotic drugs (clozapine, olanza-
pine, amisulpride, risperidone), and 4 patients were treated with a
typical antipsychotic agents (fluphenazine, flupentixol, perazine).
The chlorpromazine-equivalent dosage of antipsychotics was
869.97 mg per day (SD 472.91 mg).
Clinical Symptom Assessment
The symptomatology of all patients was assessed based on clini-
cian-rated instruments by an experienced senior psychiatrist who
was blinded to the results.
The 18-item Brief Psychiatric Rating Scale (BPRS) [51] was
administered, including the total score and the 5 subscales (anxiety-
depression, anergia, thinking disturbance, hostility-suspiciousness,
withdrawal-retardation). Furthermore, the Scale for the Assessment
of Positive Symptoms (SAPS) and the Scale for the Assessment of
Negative Symptoms (SANS) [52, 53] were utilized. The SAPS con-
tains 34 positive symptoms, whereas the SANS consists of 25 ratings
of negative symptoms in schizophrenia. The scale of each symptom
ranges from 0 (absent) to 5 (severe). The scores are compressed to 4
major positive and 5 major negative symptom scores, leading to a
global positive and a global negative score. The global positive score
contains the symptom clusters: hallucinations, delusions, bizarre
behavior, and positive thought disorder. The global negative score
contains the symptom clusters: affective flatness, anhedonia-asociali-
ty, avolition-apathy, alogia, and attentional impairment.
SEP Recording
All subjects were lying in a comfortable supine position in a
sound-attenuated dark room that was electrically shielded. They
were instructed to relax, remain motionless, with their eyes open.
Electrical transcutaneous stimulation was performed with two elec-
trodes over the median nerves on the wrists of the right and left hands
consecutively. Single constant-current square wave pulses of a dura-
tion of 0.2 s were delivered with an intensity of twice the motor
threshold on the opponens pollicis muscle and a stimulus rate of
6 Hz. Additionally, the subjects were instructed to silently count ran-
domly presented 1-kHz tones and to recall the number of counts after
each run of SEPs in order to preserve a stable level of vigilance. Error
rates in healthy subjects were less than 5%, while the patient group
performed with an error rate of less than 10%.
By using a 32-channel extended version of the 10/20-system
channel EEG, we obtained SEP recordings from Ag+/Cl– scalp elec-
trodes. Cz served as a reference. The impedance was kept below 5 kø.
Beforehand, three-dimensional electrode positions, in each individu-
al, were determined with a three-dimensional digitizer (ZEBRIS®).
The A/D rate of the amplifiers (NeuroScan®) was set at 5 kHz, and
the signals were band-pass filtered between 1 and 1,500 Hz (12 dB).
Because of artifacts due to eye movements in the range of B 100 ÌV,
peaks above 100 ÌV at any scalp electrode were rejected for averag-
ing procedures.
Data Analysis
Source Reconstruction Analysis
Finally, 4,000 artifact-free sweeps per side of stimulation were
included in the analysis. Each sweep contained 500 addresses over a
period of 100 ms, from 50 ms before to 50 ms after the stimulation.
Source reconstruction was performed individually for each subject
with dipole source analysis applying the Brain Electrical Source
Analysis (BESA 3.0: MEGIS, Munich, Germany) software to the
resulting files: the averaged waveforms were digitally filtered by a
low-pass filter of 750 Hz (24 dB/octave slope, zero phase shift) and a
high-pass filter of 20 Hz (12 dB/octave slope, forward filter). In order
to reduce the data to a single waveform weighted on the activity of
the neuronal generators of the SEPs, single dipole sources were fitted
for each subject and each side for a time period between 14 and
25 ms. To adjust the individual data for average head geometry and
conductivities, a spherical three-shell (scalp, skull, brain) head model
was used with the assumptions of a scalp thickness of 6 mm (0.33
[1/(øm)]), a skull thickness of 7 mm (0.0042 [1/(øm)]), and a brain
conductivity of 0.33 [1/(øm)] (fig. 1).
A single dipole is not an appropriate model for the early SEPs,
and to model all the different early SEPs, a more complex source
configuration with at least three dipoles is needed (for an explana-
tion, see Buchner et al. [31]). The approach, chosen with one dipole
based on the limitations of the investigated patient group, produced a
unique solution and was considered to be sufficient to demonstrate
differences in signal composition between the subgroups.
Time Frequency Analysis
Dipole parameters were exported to Matlab® (The MathWorks
GmbH). For time frequency analysis of the source, a wavelet analysis
was computed using the time-frequency toolbox of the Rice Univer-
sity (USA) resulting in a Morlet deconvolution. The program com-
putes a scalogram, a diagram based on three axes, displaying compo-
nents of frequency and energy at each time point. The frequency with
the highest energy and its corresponding time point is detected auto-
matically. In a first step, the frequency band between 40 and 450 Hz
was analyzed: the frequency with the highest energy and its time
point were determined within the range of the N20, followed by the
same analysis procedures of the frequency band between 450 and
800 Hz. The resulting values were analyzed statistically.
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Fig. 1. 32-channel montage (a) and N20 dipole source activity and source model for the grand average of all sub-
jects (b).
25 ms 2 nAm
Data:VNLavg.avr
R
BESA 3.0
1
RL1
1
1
ba RV = 16.1% (14–24 ms)
Fig. 2. Source waveform (a, b) and scalograms (c, d) of wave transformation analysis with the time point of highest
energy level in the low-frequency, 40–450 Hz (c), and in the high-frequency, 450– 850 Hz (d) range of schizophrenic
subjects.
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Statistical Analysis
The two-tailed t test was applied for group differences between
electrophysiological parameters (amplitude, latency, frequency).
Correlation coefficients for variables of SEPs and clinical psychopa-
thological scores were calculated by Spearman’s nonparametric rank
method, taking into account power analysis for the strength of the
group (· = 0.5, ß = 0.80). In order to investigate the severity of disease
symptoms, the median of the duration of illness served as a cutoff for
two groups of subjects with longer and shorter time since onset of the
first episode, followed by one-tailed t tests. Results were considered
significant at p ! 0.05. The SAS 8.0 package was used for all statisti-
cal analyses.
Results
SEPs/Electrophysiological Parameters
Comparing the sides of stimulation within each group,
there were no significant differences between the frequen-
cy ranges for left and right hands. Therefore, the data of
left and right hand stimulation were combined for further
analysis. This led to a subsequent comparison of 20 data
sets per group. Low- and high-frequency ranges were ana-
lyzed subsequently (fig. 2). The two-tailed t test was per-
formed for latencies, amplitudes, and frequencies of the
peaking points in the three-dimensional scalogram.
In all patients and controls, low- and high-frequency
(600 Hz) SEP components were observed. For both fre-
quency ranges, significant differences between the groups
of schizophrenic patients and normal controls were
found.
(1) Low-frequency range (40–450 Hz): the energy (am-
plitude) of the low-frequency maximum was significantly
higher in the schizophrenic patients compared with the
healthy controls (d.f. = 38, t = –2.14, p = 0.039). Latencies
and frequencies did not differ significantly between the
groups (table 1).
(2) High-frequency range (450–850 Hz): the latency of
the maximum of high-frequency activity as detected by
Morlet transformation was significantly delayed in the
group of schizophrenic patients (d.f. = 38, t = –2.05, p =
0.048). Frequencies and energies did not differ signifi-
cantly (table 1).
Clinical Pathopsychological Findings
Mean values, median values, standard deviations, and
ranges of the results of the assessment of positive (SAPS)
and negative (SANS) symptoms as well as global psychiat-
ric (BPRS) symptoms in all schizophrenic patients are
presented in table 2.
Table 1. Mean values (including SD in parentheses) of median nerve
SEPs in schizophrenic patients (n = 20) and healthy controls
(n = 20)
SEPs Schizophrenics Controls p
N20
Latency, ms 20.70 (1.30) 21.08 (2.13) ns
Frequency, Hz 71.71 (12.23) 74.77 (17.88) ns
Energy, ÌV2 612.19 (230.51) 476.77 (163.55) *
HFOs 
Latency, ms 19.33 (1.90) 17.98 (1.45) *
Frequency, Hz 602.31 (33.53) 597.73 (47.15) ns
Energy, ÌV2 42.75 (12.39) 36.69 (14.24) ns
* p ! 0.05. ns = Nonsignificant.
Table 2. Mean and median values (including SD in parentheses) of
scores for psychopathological symptoms in schizophrenic patients
(n = 20)
Test Mean (SD) Median Range
SAPS
Total positive score 10.1 (3.5) 9.5 4–16
Hallucinations 1.4 (1.3) 1.0 0–4
Delusions 2.2 (1.1) 2.0 0–4
Bizarre behavior 2.2 (0.8) 2.0 1–4
Formal thought disorder 2.1 (0.9) 2.0 1–4
Inappropriate affect 2.3 (1.3) 2.0 0–4
SANS
Total negative score 12.5 (4.3) 12.5 2–21
Affective flattening 2.2 (1.4) 2.0 0–4
Alogia 1.7 (1.2) 2.0 0–5
Avolition-apathy 2.9 (0.9) 3.0 1–4
Anhedonia-asociality 2.6 (0.9) 3.0 1–4
Attentional impairment 2.8 (1.0) 3.0 0–4 
BPRS
Total score 58.4 (12.3) 56.5 41–83
Anxiety-depression 13.2 (3.9) 13.0 5–21
Anergia 12.2 (3.7) 11.0 6–19
Thought disorder 12.35 (3.7) 13.0 5–18
Activation 11.4 (3.4) 11.0 5–17
Hostile-suspiciousness 9.4 (4.1) 9.0 3–19
SEPs and Clinical Relationships 
The correlations between clinical psychopathological
symptoms and HFOs are shown in table 3. There was a
significant negative correlation between HFO amplitude
and delusions (r = –0.51; p = 0.03), as well as between
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Table 3. Correlation of clinical symptoms and the N20 measures of
HFO (600 Hz) in schizophrenic patients (n = 20)
Test Latency
ms
Frequency
Hz
Energy
ÌV2
SAPS
Total positive score 0.10 –0.27 –0.37
Hallucinations –0.24 –0.32 0.04
Delusions 0.19 –0.19 –0.50*
Bizarre behavior –0.10 –0.04 –0.27
Formal thought disorder 0.20 –0.34 –0.51*
Inappropriate affect 0.28 0.09 –0.25
SANS
Total negative score 0.31 0.29 –0.15
Affective flattening 0.29 0.35 –0.15
Alogia 0.07 0.08 –0.18
Avolition-apathy 0.47* 0.29 –0.11
Anhedonia-asociality 0.08 0.30 0.18
Attentional impairment 0.36 0.16 –0.26
BPRS
Total
Anxiety-depression –0.37 –0.05 –0.02
Anergia 0.12 0.41* –0.11
Thought disturbance 0.03 –0.33 –0.40*
Activation –0.09 –0.22 –0.17
Hostile-suspiciousness 0.14 –0.12 –0.23
*p ! 0.05, · = 0.05, ß = 0.80. Values are Spearman’s correlation
coefficients.
HFO amplitude and formal thought disorder (r = –0.51;
p = 0.02). The latter was paralleled by a trend toward a
negative correlation between HFO amplitude and formal
thought disturbance in the BPRS (r = –0.40; p = 0.08).
Concerning negative symptoms of schizophrenia, the la-
tency of high-frequency SEP parameters was positively
correlated with apathy (r = 0.47; p = 0.03) and there was a
trend toward a correlation for HFO frequency and anergia
(r = 0.41; p = 0.07) as well. However, a more detailed anal-
ysis of influences of medications on apathy or anergia
did not show any positive correlation (0.46 ! p ! 0.92).
Otherwise, there were no correlations for the low-frequen-
cy SEP parameters with clinical symptoms of schizo-
phrenia.
SEPs and Medical History
Apart from a trend toward a correlation between neu-
roleptic dosage as measured by the chlorpromazine equiv-
alent and the duration of illness (r = 0.46, p = 0.07), we did
not note any significant influence of the medication on
the electrophysiological SEP parameters, on age, onset or
type of symptoms (data are not presented in detail). More-
over, there was a significant difference in the amount of
neuroleptic dosage in the patients with a duration of
schizophrenia of more than 2 years as compared with a
group with a 2-year or shorter duration (¯2 = 6.73, d.f. = 1,
p = 0.01). The duration of illness (median value) corre-
lated positively with the frequency of N20 (r = –0.50, p =
0.04). There was also a trend toward a correlation be-
tween duration of illness and delusions (r = 0.46, p =
0.06).
Discussion
In this study of 20 schizophrenic patients and their
age-matched and gender-matched controls, differences
between low- and high-frequency components of median
nerve evoked SEPs were registered with a 32-multichan-
nel EEG, followed by advanced techniques with dipole
source analysis and a wavelet transformation before and
after high-pass filtering. The purpose of the investigation
was to evaluate scalp surface EEG data of presumed intra-
cranial thalamocortical somatosensory source in relation-
ship to symptoms and severity of the disorder.
First, an augmentation in the mean amplitude of the
low-frequency energy (around N20) was detected in
schizophrenics, compared with healthy controls. This re-
sult of a higher amplitude of the early low frequency is in
accordance with previous SEP studies in schizophrenia:
the early part of SEPs in patients with chronic schizophre-
nia was found to be exceptionally stable and accentuated
[27, 28]. These findings were interpreted as an impair-
ment of thalamic filtering of the afferent sensory informa-
tion to the cortex. The stimulus barrier was considered to
be exceptionally weak in schizophrenics [28]. Remitted
schizophrenics did not show any differences in latencies
or amplitudes in an event-related study on SEPs [54],
although attention-related reduced areas and prolonged
latencies of the cognitive component N1 were observed.
The second finding of a significantly prolonged latency
of the maximum HFO activity (600 Hz) in the group of
schizophrenic patients is of interest because the HFOs
presumably reflect time processing of rapidly repeating
population spikes in thalamocortical afferences and the
receiving neocortical cell populations [48]. Based on ani-
mal data, Jones et al. [37] ascribed the cause of cerebral
high-frequency activity, obtained by single cell monitor-
ing, to a possible epiphenomenon of inhibitory interneu-
ronal activity. Furthermore, there is evidence for a pre-
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synaptically and postsynaptically generated component of
the HFOs [55]; the early presynaptic component is, most
probably, generated by specific thalamocortical axonal
terminals. So far, the cortically generated component of
HFOs has been shown to be influenced by NMDA recep-
tor antagonists [55] with possible effects on inhibitory
GABA-ergic mechanisms, which is supported by the hy-
pothesis that HFOs represent activity of GABA inhibitory
interneurons responding to thalamocortical input [38].
Glutaminergic neurons are the major excitatory pathways
linking the cortex, limbic systems, and thalamus, regions
that have been implicated in schizophrenia, with dysfunc-
tional glutaminergic and related dopaminergic neuro-
transmission [8, 56]. Consequently, under the assumption
that the investigated HFOs are of inhibitory nature, the
absence of early HFOs in the group of schizophrenics
could point to a dysfunctional inhibition of thalamocorti-
cal and early cortical afferents in schizophrenia, resulting
in higher cortical input of sensory information as ex-
pressed by enhanced amplitudes of the cortical low-fre-
quency SEPs around N20.
Moreover, if the increase in HFO latency of the schizo-
phrenic group reflects an impairment of thalamocortical
somatosensory information processing, the thalamic reti-
cular nucleus is probably involved. This nucleus selective-
ly gates neurotransmission from the thalamus to the neo-
cortex and continually regulates thalamocortical activity
[1]. Furthermore, it is thought to be related to the control
of vigilance and alertness as well as in the production of
epileptic discharges [57, 58]. Across the sleep-wake cycle,
somatosensory HFOs were found to be decreased in non-
REM states at the level of thalamus and cortex but not at
the brainstem, while the amplitude of the concomitant
N20 was dissociated [32, 38, 47]. The reticular thalamic
nucleus regulating arousal and vigilance supposedly re-
presents one main candidate for modulation of HFOs
[46].
In psychopathology, negative correlations of the HFO
energy (amplitude) were seen with the positive symptom
scale, in particular with positive thought disorder and
delusions. Additionally, there was also a trend toward a
negative correlation between HFO energy and thought
disturbance in the broader and less disease-specific
BPRS. Otherwise, patients with a long duration of illness
showed more delusions and enhanced low early frequen-
cies compared with the group with a shorter course of dis-
ease. This might point to a relationship between both for-
mal thought disorder and delusional thinking with an
altered thalamic function. In a positron emission tomog-
raphy study, Siegel et al. [22] demonstrated an association
between reduced thalamic activity and the occurrence of
schizophrenic positive symptoms (e.g. the total BPRS
score), though there were no group differences in the tha-
lamic activity between schizophrenics and controls. Tha-
lamic (and cortical) glucose metabolic rate, in particular
in the anterior and mediodorsal nucleus, was also found
to be reduced in another study with deficit schizophrenics
as compared with nondeficit schizophrenics [16]. In both
first-episode and chronic schizophrenics, a reduced blood
flow in prefrontal areas and an enhanced blood flow in
thalamic (and cerebellar) regions has been observed [24].
A disturbance of the integrity of the lateral fronto-thalam-
ic-neocortical circuit may lead to sensory overstimula-
tion, disorientation, and mnestic deficits with resulting
severe psychological and cognitive deficits. This may also
occur in patients with lesions of the dorsomedial nucleus
or the bidirectional fibers connecting the thalamus and
the frontal lobes [1, 59]. Our finding of a correlation
between thought disorder and abnormal HFOs, assumed
of thalamocortical origin, is also supported by findings in
a rare case of a patient who presented with bilateral para-
median thalamic infarcts and subsequently decreased tha-
lamic and basal ganglia blood flow: despite a characteris-
tic diencephalic amnesia, she showed a bizarre, severely
disordered, and at times incoherent speech in contrast to
a relatively preserved lexical and morphosyntactic lin-
guistic production; this finding was interpreted as a sur-
face manifestation of a thought disorder [60].
In the past, a disturbance of thalamic filtering as a
pathophysiological basis of positive symptoms in schizo-
phrenia was postulated by Fish [5]. As early as 1911,
Bleuler [61] had considered the ‘loosening of associations’
a fundamental core symptom of schizophrenia. At the
time when this idea was somehow reconstituted as ‘cogni-
tive dysmetria’, with disturbance of perception, encoding,
retrieval, discrimination of information and prioritiza-
tion of experiences [9], it was emphasized that the linkage
in the breakdown of ‘collective’ thalamic components
could represent the basis of fragmentation of thought pro-
cesses as in schizophrenia [10]. Regular mechanisms of
filtering and inhibiting irrelevant information at the tha-
lamic level before it reaches the neocortex may have
become dysfunctional. In this context, the absence of ear-
ly HFOs could represent a dysfunctional thalamic inhibi-
tion with enhanced amplitudes of N20 and increased
prevalence of positive schizophrenic symptoms of
thought processes. Sensorimotor gating alterations as
measured by prepulse inhibition [62] were also shown to
correlate with disturbed thinking (Rohrschach test) and
delusions (SAPS). Another EEG approach suggested that
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cortical EEG alpha rhythm is correlated with alpha
rhythm recorded from the thalamus and related thalamic
neuronal activity expressed as glucose metabolic rate in
humans [63]. However, this pattern was not observed in
schizophrenics [64].
As negative symptoms may be induced by antipsychot-
ic medications [65], inverse correlations between anergia
(BPRS) and maximum frequency of HFOs may be ex-
plained by drug effects. There was also a positive correla-
tion between avolition/apathy (SANS) and HFO latency.
In some functional studies with schizophrenics, a correla-
tion of negative symptoms or neuroleptic responsiveness
with impaired thalamic perfusion was observed [66]. In
our study, there was no correlation between the amount of
the neuroleptic dosage (chlorpromazine equivalent) and
psychopathological symptoms. The majority of schizo-
phrenics were treated with atypical antipsychotics. Al-
though Klostermann et al. [48] did not find any effects of
anticonvulsants, they demonstrated a higher variability of
both bursts and N20 in a mixed sample of epileptic
patients compared with healthy controls. Patients with
Parkinson’s disease exhibited an increased early high-fre-
quency component, while an augmented later burst com-
ponent around 25–33 ms was found in patients with myo-
clonus epilepsy [67].
Our study has methodological limitations. First, the
study size of our patient group was rather small. Since the
investigation required some effort by the participants, we
considered the number of investigated subjects to be suffi-
cient, based on similar sample sizes in basic research [49].
Considering that the subjects chosen had to be patient and
vigilant enough to go through the experimental session,
the findings are not fully representative for the group of
schizophrenics. Additionally, the number is not sufficient
to effectively differentiate subgroups. Another implica-
tion is that some of the nonsignificant results may indeed
be false-negative values.
Hence, a further limitation of the study is that all
patients were taking antipsychotic drugs before and dur-
ing the study. Previous results showed that single dosages
of haloperidol were not affecting the amplitude of the ear-
ly median nerve SEP in healthy individuals [68]. Al-
though the effects of haloperidol in metabolic imaging
studies of schizophrenics are contradictory [20, 21], a
reduction of glucose metabolism in basal ganglia and thal-
amus was demonstrated after withdrawal of the drug [23].
Furthermore, regional blood flow abnormalities have not
always been due to chronicity of illness or effects of medi-
cations [24]. Thalamic size may be increased by medica-
tions [15], although this finding has not been confirmed.
Such effects were also shown for other subcortical struc-
tures [69]. Moreover, in the meta-analysis of comparable
magnetic resonance imaging studies of Konick and Fried-
man [18], most of the patients presenting moderately
smaller absolute and relative thalamic sizes compared
with controls in the meta-analysis were medicated. Al-
though the majority of our patients were treated with
atypical antipsychotics, comparable data of effects of dif-
ferent types of antipsychotics on SEPs are not available.
Only in animal studies, chronic treatment with clozapine
and haloperidol was shown to change regulation of sub-
cortical D1 and D2 dopaminergic receptors of the primary
somatosensory cortex [70]. Still, our results of an increase
in the low-frequency energy of the N20 signal is in accor-
dance with the few available SEP investigations in neuro-
leptic-free schizophrenics [27]. Caution was also applied
to the usage of benzodiazepines since lorazepam was
found to increase the latency of HFOs and to decrease
frequencies of N20 and HFOs in a magnetoencephalogra-
phy study [71]. Thus, patients who needed benzodiaze-
pines during the same hospitalization were excluded from
this study.
Although caution is indicated when linking aberrant
cortical oscillations with characteristic cognitive deficits
resulting from a dysfunctional prefrontal-thalamic-cere-
bellar circuitry [9], HFOs might offer an understanding of
the organization of sensory pathways in relation to per-
ception and also put new insight into perceptual and cog-
nitive deficits in schizophrenia. Fast thalamocortical os-
cillations and their associated intracellular events broad-
en the understanding of the classical picture of cellular
processes underlying the evoked potential complex [37].
Still, the question as to whether electric alterations linked
to thalamocortical dysfunction represent the cause or the
consequence of positive schizophrenic symptoms remains
unanswered, of course; yet HFOs should be considered a
specific tool for investigation of abnormalities in somato-
sensory signal processing. These investigations should be
conducted in schizophrenic subgroups.
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